Intravenous endostatin gene transfection results in tumor suppression in a murine pulmonary metastasis model. We transfected the endostatin gene at different times, in order to achieve an optimal protective effect. pST2-Endo encoding murine endostatin was injected in a complex with cationic lipid. Pulmonary metastases were caused by intravenous injection of murine fibrosarcoma cells. Mice were observed for 14 days following fibrosarcoma cell inoculation (FSI). In the study groups, the animals were transfected with pST2-Endo at three different times: 2 days before and 3 and 7 days after FSI. In the group transfected with pST2-Endo 2 days before FSI, the weights of the lungs and tumor-occupied area ratio were significantly less than in the other groups. Significant inhibition of tumor neovascularization was documented by means of CD31 immunohistochemistry. The effect of repeated endostatin transfection on survival after FSI was determined. Animals repeatedly transfected with the endostatin gene survived significantly longer than the groups treated with a single endostatin gene transfection. A stable endostatin-expressing fibrosarcoma transfectant was created and tested for migration and invasion. Compared with controls, endostatin expression reduced migration and invasion by 15%. It is concluded that endostation gene transfection before FSI and repeated transfection thereafter results in significant tumor suppression. Cancer Gene Therapy (2004) 2 Systemic administration of angiogenic inhibitors has been shown to reduce the growth of established tumors and metastases. Antiangiogenic therapy has recently attracted intense interest because of its broad-spectrum action, low toxicity, and absence of drug resistance.
A ngiogenesis is one of the most important steps in tumor growth and metastasis. 1 It is controlled by a balance of angiogenic stimulators and inhibitors. 2 Systemic administration of angiogenic inhibitors has been shown to reduce the growth of established tumors and metastases. Antiangiogenic therapy has recently attracted intense interest because of its broad-spectrum action, low toxicity, and absence of drug resistance. 3 Recently, several naturally occurring angiogenesis inhibitors have been identified. Endostatin, a 20 kDa C-terminal fragment of type XVIII collagen, is one of the most potent of these. 4 Although detailed mechanisms of its action are still unclear, it is known to inhibit endothelial cell proliferation and migration, 5 promote apoptosis, 4 and induce cell cycle arrest in endothelial cells. 6 There are some major problems in translating endostatin therapy to the clinic. One is the difficulty of producing the protein in sufficiently large quantities for chronic treatment, although recently, stable and soluble forms of endostatin produced by Escherichia coli or yeast cells have been reported. 7, 8 Additionally, continuous administration of antiangiogenic agents is required over a long period of time. It has been shown that continuous administration of endostatin was much more effective than i.p. or s.c. administration. 9 Therefore, gene transfection is one of the most promising methods of administration. In our previous study, we used gene transfer of this antiangiogenic agent complexes with cationic vectors and demonstrated the efficacy of endostatin gene transfer in a murine lung metastasis model. 10 Multistage carcinogenesis theories propose that each antiangiogenic drug would be most efficacious at specific stages of tumor progression. 11 We hypothesized that endostatin transfection may also have an optimal timing for maximal tumor suppression. In the present study, we have investigated the effect of intravenous delivery of the endostatin gene complexes with cationic lipid given at different times, including pretreatment prior to the formation of lung metastasis. We have determined the optimal timing of endostatin transfection in this model.
In addition, we have performed repeated transfection. With cationic liposomal transfection, repeated injection is feasible in order to obtain extended effects and it is in fact one of the most attractive advantages of this approach.
We therefore determined the effect of repeated endostatin gene transfection on the survival of animals after fibrosarcoma cell inoculation.
Materials and methods

Animals
Male C3H mice, 7-9 weeks old, were obtained from Charles River Japan Inc. (Yokohama, Japan). Research was conducted according to the Guidelines for the Care and Use of Laboratory Animals of Nagoya City University Medical School. The experimental protocol was approved by the Institutional Animal Care and Use Committee of Nagoya City University Medical School.
pST2-Endo construct
The construction of plasmid pST2-Endo has been described previously. 7 Total RNA was extracted from C3H mouse liver using ISOGEN (Nippon Gene, Toyama, Japan) and reverse transcription was performed with Moloney murine leukemia virus reverse transcriptase (SUPERSCRIPT II; Gibco BRL, Gaithersburg, MD). A cDNA coding for mouse endostatin was amplified by PCR methods using oligonucleotide primers, which included KpnI and EcoRI restriction sites at the 5 0 and 3 0 ends, respectively. These PCR products and pSecTag2 (Invitrogen, Carlsbad, CA) were digested with KpnI and EcoRI, and then ligated to one another. This plasmid was designated pST2-Endo. The parent plasmid pSecTag2 (pST2) was used as a control. DNA sequence analysis confirmed that the mouse endostatin cDNA sequence was inserted into the proper reading frame without mutations.
Intravenous lung transfection using cationic lipid
Genzyme cationic lipid #67 (GL-67; N4-spermine cholesterylcarbamate), the neutral colipid DOPE, and stabilizing lipid DMPE-PEG 5000 were coformulated (GL-67: DOPE: DMPE-PEG 5000 , 1: 2: 0.05, mol/mol/mol); they were provided by Genzyme Corporation (Framingham, MA). GL67/DOPE/DMPE-PEG 5000 and plasmid DNA were mixed and incubated before administration. The final concentrations were 1 mmol/l cationic lipid and 0.6 g/l plasmid DNA. Amounts of 60 mg plasmid DNA complexes with 100 nmol GL67/DOPE/DMPE-PEG 5000 in 100 ml sterile water were injected via the mouse tail vein.
Cell line and lung metastasis model
The murine fibrosarcoma cell line NFSa Y83 was kindly provided by Dr Koichi Ando (National Institute of Radiological Sciences, Chiba, Japan) and was grown in minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS). Experimental lung metastases were established in mice by intravenous injection of 5 Â 10 5 NFSa Y83 cells in 100 ml of saline solution via the tail vein.
Quantitative RT-PCR
To determine the important parameters of endostatin gene transfection, endostatin messenger RNA was assessed with a quantitative reverse transcription-polymerase chain reaction (RT-PCR) method using LightCycler (Roche Molecular Biochemicals, Mannheim, Germany). Changes in gene expression were followed for 2 weeks after endostatin transfection. The lung samples were homogenized and RNA was extracted using ISOGEN (Nippon Gene, Toyama, Japan). Any residual DNA was removed from the RNA by incubating the RNA extract with RNase-free DNase I. An amount of 1 mg of RNA was reverse transcribed by SUPERSCRIPT II with 0.5 mg oligo (dT) [12] [13] [14] [15] [16] (Amersham Pharmacia Biotech, Inc., Piscataway, NJ). The reaction mixture was incubated at 421C for 50 minutes followed by incubation at 721C for 15 minutes. A volume of 1 ml of the reaction mixture ( 1 20 th of the total amount of the reaction mixture) was used with LightCycler FastStart DNA Master SYBR Green I kits (Gibco BRL, Gaithersburg, MD). Mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expression was used as an internal control. The PCR primers coding exogenous endostatin were designed to include the Igk-chain leader sequence located forward of the frame encoding endostatin to distinguish it from endogenous endostatin. The GAPDH PCR primers were designed by OLIGO software from the previously reported mouse GAPDH sequence. The cycling conditions in both GAPDH and endostatin PCR were as follows: initial denaturation at 951C for 10 minutes, followed by 50 cycles of amplification consisting of 15 seconds at 941C, 5 seconds at 561C, and 20 seconds at 721C.
Enzyme immunoassay
To determine parameters of endostatin transfection, the endostatin protein concentration in serum was measured using an enzyme immunoassay (EIA) technique. Changes in endostatin protein concentration were followed for 2 weeks after endostatin transfection. Mouse serum was separated from blood collected at the time of killing. Murine endostatin levels were measured by the EIA technique using Chemikine Mouse Endostatin EIA Kits (Chemicon International, Inc., Temecula, CA) according to the manufacturer's instructions. Rabbit anti-mouse endostatin polyclonal antibody was used and the optical density of the final reaction solution was read at 490 nm with a microplate reader.
Tumor-occupied area ratio
Pathology sections stained with hematoxylin and eosin were evaluated by a scanner with the Photoshop software. Values were assessed by NIH image software and background area and tumor-occupied area were calculated and compared in the different groups. Fibrosarcoma cell nuclei were well-stained with hematoxylin and possessed little cytoplasm, making the tumor-occupied area well-demarcated and allowing quantification by densitometry.
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Microvessel density in immunohistochemistry
To determine the effect of treatment on tumor neovascularization, microvessel density was visualized using CD31 immunohistochemical staining. 11 Lung specimens were snap-frozen, sliced into 10-mm sections, and fixed in acetone. Endogenous peroxidases were blocked with 0.3% hydrogen peroxide in methanol and 5%(w/v) nonfat dried milk. The sections were incubated at room temperature overnight with a rat anti-mouse CD31 monoclonal antibody (BD Pharmingen, San Diego, CA) (1:800) in PBS. Subsequently, a HISTOFINE SAB-PO Kit (Nichirei, Tokyo, Japan) was used according to the manufacturer's instructions with modifications. Sections were incubated with biotinylated secondary anti-rat antibody (1:600). A solution containing 3,3
0 -diaminobenzidine-tetrahydrochloride (MERCK, Darmstadt, Germany) and 0.2% hydrogen peroxidase was used as the chromogen. The images of CD31-stained sections were acquired using a digital camera, Leica DC 500 (Leica Microsystems Ltd, Heerbrugg, Switzerland) and the neovascular area was calculated by the software of Leica Image Manager.
Repeated transfection procedures
The effect of repeated transfection on survival after tumor cell inoculation was determined. Three groups were designed. The control group was treated with saline injection 2 days before tumor cell inoculation via the tail vein. A single transfection group was injected with pST2-Endo plasmid complexes 2 days before tumor cell inoculation. A repeated transfection group was injected with pST2-Endo plasmid complexes 2 days before tumor cell inoculation and once every following week until the first death was observed in this group. The survival was observed in groups.
Generation of stable transfectants
pST2-Endo or control pST2 was transfected into the murine fibrosarcoma cell line, NFSa Y83. Stable transfectants were selected by zeocin and protein expression was assessed by immunofluorescence. One of the endostatin-transfected NFSa Y83 clones secreted M r 25,000 endostatin protein (data not shown). Protein production was detected even after the second and third passages, and gene expression was confirmed using RT-PCR methods. A control clone was transfected with empty vector.
Migration and invasion assays
Cell migration and invasion assays were carried out using the BD FALCON HTS Fluoroblok insert and BD biocoat angiogenesis systems (Becton Dickinson Labware, Franklin Lakes, NJ). Endostatin stable transfectants and controls were assessed according to the manufacturer's instructions. Cultured cells from the second passage were used for the invasion and migration studies. A total of 1 Â 10 5 cells per well were labeled with calceinacetoxymethyl ester and incubated for 24 hours on the Falcon inserts with a fluorescence-blocking polyethylene terephthalate membrane (8 mm pore size) coated with matrigel matrix or uncoated. Each cell line was incubated on three replicate wells and assessed. Fluorescence of cells that migrated through the membrane was measured on a fluorescence plate reader. However, we did not measure the endostatin protein or gene expression during the assay of cell migration and invasion.
Statistical analysis
All values are presented as the mean7standard deviation. One-way analysis of variance with pairwise comparison by Fisher's method was employed. Survival curves were calculated by the Kaplan-Meier method and compared using the logrank test. Differences were considered significant when the P-value was less than 0.05.
Results
Exogenous endostatin gene expression in the lung by quantitative RT-PCR
To determine parameters of endostatin gene transfection, endostatin messenger RNA in the lung was assessed with a quantitative RT-PCR method LightCycler (Roche Molecular Biochemicals, Mannheim, Germany) (Fig 1) . Specific PCR primers for exogenous endostatin were designed to include the Igk-chain leader sequence located forward of the reading frame encoding endostatin in order to distinguish exogenous from endogenous endostatin. Exogenous endostatin gene expression in the lung was then assessed before and 24 hours, 72 hours, 7 days, and 14 days after transfection. Exogenous endostatin gene expression was standardized against the Figure 1 Endostatin gene expression by quantitative RT-PCR. Exogenous endostatin mRNA was assessed at various times before and after transfection by a quantitative RT-PCR method using LightCycler. Exogenous endostatin mRNA was standardized against mouse GAPDH mRNA. Intact lungs were used as a control before transfection. There is a significant difference between before and 24 hours after transfection (*Po0.05).
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Serum endostatin protein assessed by EIA
To further characterize endostatin gene transfection parameters, the presence of endostatin protein, both endogenous and exogenous forms, in serum was quantified with the EIA method (Fig 2) . Expression of the endostatin protein was much delayed compared to the mRNA expression. Maximal serum endostatin was seen 7 days after transfection and was significantly higher at this time than at other time points (P ¼ 0.003, 0.003, 0.022, and 0.004, vs. control serum, 24 hours, 72 hours, and 14 days after transfection, respectively).
Inhibition of tumorigenesis by endostatin gene transfection
Animals were divided into five groups. Three endostatin transfection groups and two control groups were designed (n ¼ 8 for each group). The animals in one control group (group I) were injected with saline solution 2 days before fibrosarcoma cell inoculation (FSI), whereas in the other (group II), the animals were injected with 60 mg of control plasmid (pST2) complexes with GL67/DOPE/DMPE-PEG 5000 2 days before FSI. In the study groups, the animals were injected with 60 mg of pST2-Endo plasmid complexes with GL67/DOPE/DMPE-PEG 5000 at three different times: 2 days before and 3 and 7 days after FSI (groups III, IV, and V, respectively). At 14 days after FSI, mice were killed. The heart and lung blocks were removed en bloc after collecting the blood. 10 The extent of lung metastasis was assessed by the weight of the lung samples and the tumor-occupied area ratio. Lung samples were weighed and assessed by pathology. The coronal sections of lung samples with maximal slice area were stained with hematoxylin and eosin and assessed for the area occupied by the tumor using a densitometric method.
All animals survived for 2 weeks after tumor cell inoculation. In Figure 3a , typical mouse lung samples from each group are shown. In control mice from group I, the whole surface of the lungs was consistently replaced with numerous small metastatic nodules. Some nodules became confluent and formed bigger tumors. In the control mice from group II, receiving empty pST2 vector, the amount of metastatic tumor nodules was clearly decreased compared with the untreated lungs in group I.
In all mice of group III, transfected with the endostatin gene 2 days before FSI, only a few small nodules were seen on the surface of the lungs. In group IV animals transfected 3 days after FSI, more tumor nodules were observed than in group III animals. In the lungs of group V animals, transfected 7 days after the tumor cell inoculation, many more tumor nodules were present and the lungs appeared similar to those of group I control animals without transfection.
The weight of the lungs was measured and is compared in Figure 3b . In group III animals, lung weight was significantly lesser than in the other study groups (P ¼ 0.008, vs. group IV and Po0.001, vs. group V) or control group I (Po0.001). In group II animals, the lung weight was significantly reduced compared to that in group I animals (P ¼ 0.011).
In an additional study, to analyze the tumor suppressive effect of pST2 with GL67/DOPE, pST2 without GL67/DOPE, pST2-Endo without GL67/DOPE, or GL67/DOPE without plasmid was injected 2 days before FSI. At 14 days after FSI, animals were killed and the weight of the lungs was compared (Fig 3c) . Injection of pST2 alone without GL67/DOPE failed to show any suppression of tumor growth. The same was true for GL67/DOPE injection alone without plasmid. Injection of pST2-Endo without GL67 showed some tumor suppression compared with pST2 or GL67/DOPE alone. However, the tumor suppressive effect was clearly less than when the complex of pST2-Endo and GL67/DOPE was used (Fig 3b) .
The tumor-occupied area ratio was evaluated using a densitometric method (Fig 4) . The metastatic lung tumor nodules were stained much darker than the lung parenchyma and the area occupied by the tumor was readily distinguished by adjusting the sensitivity level of scanning. The tumor-occupied area ratio in group III was significantly lesser than in the other groups. There were no significant differences between groups II and IV or groups I and V. There were significant differences in all the other comparisons.
These results suggested that pST2-Endo treatment 2 days before FSI suppressed lung tumor formation. Figure 2 Serum endostatin levels by EIA. Serum endostatin was assessed by EIA at various times before and after transfection. The serum of untreated animals served as a control. The maximal level of serum endostatin was seen 7 days after transfection. It was significantly higher at 7 days than at other times (*Po0.05).
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Microvessel density in immunohistochemistry
An additional two animals each received saline or pST2-Endo 2 days before FSI (as in groups I or III, respectively) (Fig 5) . Lung samples were examined by immunohistochemistry. Microvessel density was visualized using CD31 immunohistochemical staining. Tumor nodules of similar size from each group were compared. 12 In lung specimens from control animals, numerous microvessels were stained with CD31 antibody (Fig 5a) . In animals treated with pST2-Endo 2 days before FSI, however, very few cells stained with anti-CD31 in the nodules (Fig 5b) . In these animals, tumor neovascularization was apparently inhibited. Three sections of each sample were analyzed and microvessel density was expressed numerically. The microvascular area ratio was 6.371.0% in a control group vs. 2.070.8 in an endostatin-treated group (Fig 5c) . Tumor neovascularization was clearly inhibited in the group treated by pST2-Endo.
Effect of repeated transfection
In another experiment, the effect of repeated transfection on survival after tumor cell inoculation was determined (Fig 6) . Three groups, a saline control group, a single transfection group with pST2-Endo, and a repeated transfection group with pST2-Endo, were examined. The first death in each group was observed 12, 19, and 27 days after FSI in these three groups, respectively. The animals in the repeated transfection group were injected with pST2-Endo five times (2 days before FSI and 5, 12, 19, 26 days after FSI). The animals in the single transfection group survived longer than in the saline control group (P ¼ 0.003). Furthermore, the animals in Figure 3 Inhibition of tumorigenesis by endostatin gene transfection. Two control groups and three endostatin gene transfection groups were designed. The animals in one control group (group I) were injected with fibrosarcoma (FS) cells without transfection and in the other control group (group II) the animals were injected with 60 mg of pST2 plasmid complexes with GL67/DOPE 2 days before FS inoculation. In the study groups, the animals were injected with 60 mg of pST2-Endo plasmid complexes with GL67/DOPE/DMPE-PEG 5000 at three different times: 2 days before and 3 and 7 days after FSI (groups III, IV, and V, respectively). At 14 days after FS inoculation, mice were killed. (a) Typical appearance of lung samples in each group. (b) The weight of the lungs in each group. In group III animals, the weight of the lungs was significantly less than that in the other study groups and in control group I. In group II animals, the lung weight was reduced significantly compared with group I animals. (c) Analysis of tumor suppression by plasmid alone or liposomal vector alone. pST2 without GL/67, pST2-Endo without GL67/DOPE, or GL67/DOPE without plasmid was injected 2 days before FSI. pST2 or GL67/DOPE injection alone did not show any suppression of tumor growth. pST2-Endo injection without GL67 showed some tumor suppression compared with pST2 or GL67/DOPE alone. However, the tumor suppressive effect was much less than when the complex of pST2-Endo and GL67/DOPE was used. The experiment (c) (closed columns) was not compared directly to (b) because this additional experiment was performed on a different day (*Po0.05).
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Inhibition of migration and invasion abilities
Cell migration ability was assessed by measuring fluorescence of the cells that migrated through the PET membrane without matrigel matrix coating (Fig 7) . In stable endostatin transfectants, migration was suppressed by 15% compared to control cells. Invasion ability was also assessed by measuring fluorescence of the cells that migrated through the PET membrane with matrigel matrix coating. This was found to be reduced by 15.4% in the stable transfectants.
Discussion
It has been shown that viral vectors are excellent carriers to transfect exogenous genes in in vivo studies. They, however, may cause inflammation and immunological response on repeated injection. Cationic lipids are also effective for gene transfer and intravenous administration of cationic lipids has been reported to result in a high level of gene expression in the lung. 13 Although the effect is transient, repeated administration to achieve continuous expression is possible. 14 In the previous study, the five organs, lung, heart, liver, kidney, and spleen did not reveal any pathological findings such as those caused by immunological reactions. In the present study, there were no obvious symptoms after transfection in mice, unlike those commonly seen after adenoviral transfection. This is a significant advantage of the use of cationic lipid.
One single injection of the endostatin gene complex resulted in significant gene expression. Maximal expression appeared 24 hours after transfection and was maintained over 2 weeks, although at lower levels. Maximal protein production appeared 7 days after the transfection with a delay following the peak of mRNA expression. It is difficult to explain but possible speculation will be mentioned. Some of the lipid gene complexes traversing the lung parenchyma might be captured in the liver, muscle, or other organs. In striated muscle, for example, the protein production may be delayed and prolonged if it is present at all. The lag period before maximal serum endostatin levels are reached may be due to production not from the lungs but from other, unidentified, organs. The serum level of endostatin in the present study was not as high as in an adenoviral transfection model reported recently. 15, 16 It is difficult to define functionally effective serum levels of endostatin because some reports on animal models with high serum levels of endostatin nonetheless failed to show any antitumor effects. 17 These reports indicated temporary high serum levels of endostatin following subcutaneous or intraperitoneal injection of endostatin. In a recent report, endostatin was found to be much more effective when administered by continuous injection even with a much lower dose than by a daily subcutaneous injection with a much higher dose. 9 If it is possible to produce endostatin continuously at the target organ site in situ even with a low dose, the effect of endostatin at the target organ would be maximal. It may have the same effect as a high serum level of endostatin produced from other organs. Organ-targeted transfection will not affect other organs and can avoid possible unwanted side effects following systemic administration of endostatin. To test these hypotheses, we have performed lung transfection using cationic lipids. Our method is not strictly organ targeted but the maximal endostatin gene expression was indeed observed in the lung. Administered cationic lipid/plasmid complexes via the tail vein are expected to reach the pulmonary capillary endothelium and affect the whole lung endothelium. We used a multiple pulmonary metastases model induced by intravenous tumor cell injection as a read-out for efficacy. This model proved useful to test the effect of endostatin gene transfection in pulmonary endothelium.
To determine the optimal timing of endostatin gene transfection, three different treatment schedules were designed. In our previous study, 10 endostatin gene transfection was performed 3 and 7 days after fibrosarcoma inoculation. There were no significant differences between the groups injected on days 3 and 7, but there was a tendency for transfection on day 3 to be more effective than on day 7. It has been suggested that for each antiangiogenic drug there will be an optimal timing of delivery depending on the stage of target tumor carcinogenesis. 11 Endostatin was reported to be the most efficacious drug for treating small preangiogenic tumors. Figure 4 Effect of endostatin gene transfection on lung metastasis formation assessed by tumor-occupied area ratio. The nuclei of fibrosarcoma cell were well-stained with hematoxylin and the mass of cytoplasm was small. The tumor-occupied area was stained darker than the lung parenchyma and was assessed by a densitometric method. The ratio in group III was significantly less than in the other groups.
Endostatin gene transfection using cationic lipid M Yano et al This suggests that endostatin gene transfection may be more effective at earlier periods of tumor development. As expected, we found that transfection 2 days before tumor cell inoculation was significantly more effective in inhibiting tumor growth than later transfection. In the study using stable transfectants, the migration and invasion abilities of fibrosarcoma cells were significantly decreased by endostatin gene transfection. This primary inhibition of tumor cell migration and invasion may be one of the reasons why endostatin gene transfection before tumor cell inoculation was more effective. In clinical practice, it is not easy to apply endostatin gene transfection to treatment for metastatic tumors, but this strategy may be applicable to treatment of patients with minimal residual disease but a very high probability of tumor recurrence after surgery.
In the control transfection group with pST2-GL67/ DOPE, significant tumor suppression was also observed (Fig 3b) . We have performed additional experiments to study this effect. pST2 injection without GL67/ DOPE or GL67/DOPE injection without plasmid did not result in any suppression of tumor growth. Recently, antitumor effects of lipoplex containing bacterial plasmids, the so-called ''CpG motif effect'' has been reported. 18, 19 Lipoplex and lipopolyplex with the CpG motif elicited a Th-1 cytokine (TNF-alpha, IL-12, and IFN-gamma) response, stimulated NK cell activity, and inhibited tumor growth. We suggest that the tumor suppression seen in these controls was due to the CpG motif effect.
Repeated transfection of the endostatin gene resulted in significant prolongation of survival time compared with a single injection of pST2-Endo or saline (Fig 7) . Repeated transfection is one of the advantages of gene delivery by cationic lipids as stated before.
The effect of endostatin gene transfection was apparent while the tumor remained small. However, the tumor suppressive ability decreased gradually as the tumor grew and all the animals eventually died of the disease. Higher dose gene transfection or more effective transfection methods still need to be developed to achieve permanent tumor dormancy.
Endostatin is one of the most attractive agents to treat malignancies. Recently, phase I clinical trials with endostatin were performed and no obvious toxicity has been reported. 20 Since the recruited patients presented with solid tumors that had progressed on standard therapies, a clinical benefit of endostatin could not be shown. The present study suggests that the optimal timing of endostatin treatment for maximal tumor suppression activity may be during the preangiogenic small tumor stage. Endostatin gene therapy may be effective in selected patients with smaller tumor burdens. Endostatin gene transfection using cationic lipid
